Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

RSV prevention drug shows promise in first year of use

NCT ID NCT07177508

Knowledge-focused Sponsor: Nicola Irwin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how a new medicine called nirsevimab affected RSV infections and hospital stays in children under 2 years old in the Australian Capital Territory. Researchers used routine health data from over 2,300 kids to compare RSV cases and emergency visits before and after the medicine was introduced. The goal was to see if nirsevimab helped reduce the burden of RSV in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nirsevimab
What this could lead to
If successful, this study could show that nirsevimab reduces RSV-related hospital visits in young children, supporting its wider use for prevention.
What could go wrong
This is an observational study, not a controlled trial, so it can't prove cause and effect. Results may be influenced by other factors like changes in virus spread or healthcare use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,355 people

The number who actually took part.

Started

Dec 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study is set in the Australian Capital Territory, a small Australian jurisdiction with a single acute paediatric service provider.

Ages

Up to 2 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * child aged less than 2 years * laboratory confirmed RSV Exclusion Criteria: * n/a

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory syncytial viral (RSV) infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Infections respiratory syncytial virus bronchiolitis respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory syncytial viral (RSV) infection Respiratory syncytial virus hospitalizations Respiratory syncytial virus prevention

Contacts and locations

Locations

  • The Canberra Hospital

    Garran, Australian Capital Territory, 2605, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.